Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-Bacterial Agents | 7 | 2013 | 333 | 0.510 |
Why?
|
Daptomycin | 5 | 2013 | 7 | 0.440 |
Why?
|
Gout Suppressants | 1 | 2010 | 1 | 0.350 |
Why?
|
Urate Oxidase | 1 | 2010 | 1 | 0.350 |
Why?
|
Tumor Lysis Syndrome | 1 | 2010 | 1 | 0.350 |
Why?
|
Drug Dosage Calculations | 1 | 2010 | 7 | 0.350 |
Why?
|
Hyperuricemia | 1 | 2010 | 3 | 0.350 |
Why?
|
Pharmacy Service, Hospital | 1 | 2009 | 11 | 0.340 |
Why?
|
Body Weight | 1 | 2010 | 137 | 0.330 |
Why?
|
Anti-HIV Agents | 1 | 2009 | 69 | 0.320 |
Why?
|
Gram-Positive Bacterial Infections | 3 | 2013 | 52 | 0.300 |
Why?
|
beta-Lactams | 3 | 2011 | 9 | 0.250 |
Why?
|
HIV Infections | 1 | 2009 | 457 | 0.240 |
Why?
|
Staphylococcus aureus | 3 | 2015 | 63 | 0.220 |
Why?
|
Staphylococcal Infections | 3 | 2015 | 144 | 0.190 |
Why?
|
Antifungal Agents | 2 | 2011 | 43 | 0.170 |
Why?
|
Pharmacists | 2 | 2009 | 17 | 0.160 |
Why?
|
Enterococcus | 3 | 2013 | 51 | 0.150 |
Why?
|
Retrospective Studies | 9 | 2015 | 3220 | 0.150 |
Why?
|
Gram-Negative Bacterial Infections | 2 | 2008 | 24 | 0.140 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 19 | 0.130 |
Why?
|
Infant, Extremely Low Birth Weight | 1 | 2015 | 19 | 0.130 |
Why?
|
Anesthetics | 1 | 2015 | 20 | 0.130 |
Why?
|
Cefazolin | 1 | 2015 | 3 | 0.130 |
Why?
|
Oxacillin | 1 | 2015 | 2 | 0.130 |
Why?
|
Methicillin | 1 | 2015 | 7 | 0.120 |
Why?
|
Child Development | 1 | 2015 | 67 | 0.120 |
Why?
|
Middle Aged | 10 | 2015 | 8403 | 0.120 |
Why?
|
Humans | 17 | 2015 | 25692 | 0.120 |
Why?
|
Drug Resistance, Bacterial | 2 | 2011 | 47 | 0.110 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2015 | 187 | 0.110 |
Why?
|
Adult | 8 | 2015 | 7336 | 0.110 |
Why?
|
Enterococcus faecalis | 1 | 2013 | 3 | 0.110 |
Why?
|
Endocarditis | 1 | 2013 | 6 | 0.110 |
Why?
|
Enterococcus faecium | 1 | 2013 | 11 | 0.110 |
Why?
|
Treatment Outcome | 5 | 2015 | 3231 | 0.110 |
Why?
|
Analgesics, Opioid | 1 | 2015 | 209 | 0.100 |
Why?
|
Male | 10 | 2015 | 13917 | 0.100 |
Why?
|
Carbapenems | 1 | 2011 | 39 | 0.090 |
Why?
|
Female | 10 | 2015 | 14273 | 0.090 |
Why?
|
Amphotericin B | 1 | 2011 | 6 | 0.090 |
Why?
|
Drug Carriers | 1 | 2011 | 7 | 0.090 |
Why?
|
beta-Lactam Resistance | 2 | 2008 | 14 | 0.090 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2011 | 7 | 0.090 |
Why?
|
Renal Insufficiency | 1 | 2011 | 13 | 0.090 |
Why?
|
Methicillin Resistance | 2 | 2008 | 23 | 0.090 |
Why?
|
Aged | 7 | 2015 | 8501 | 0.090 |
Why?
|
Microbial Sensitivity Tests | 4 | 2013 | 75 | 0.090 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 17 | 0.090 |
Why?
|
Drug Costs | 1 | 2010 | 13 | 0.090 |
Why?
|
Uric Acid | 1 | 2010 | 14 | 0.090 |
Why?
|
Medication Therapy Management | 1 | 2009 | 4 | 0.090 |
Why?
|
Cost Savings | 1 | 2010 | 36 | 0.090 |
Why?
|
Influenza, Human | 1 | 2010 | 39 | 0.090 |
Why?
|
Medication Errors | 1 | 2009 | 14 | 0.080 |
Why?
|
Candidiasis | 1 | 2009 | 22 | 0.080 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 124 | 0.080 |
Why?
|
Antiviral Agents | 1 | 2010 | 66 | 0.080 |
Why?
|
Shock, Septic | 1 | 2009 | 57 | 0.080 |
Why?
|
Nurses | 1 | 2009 | 50 | 0.080 |
Why?
|
Professional Competence | 1 | 2008 | 32 | 0.070 |
Why?
|
Bacterial Infections | 1 | 2007 | 41 | 0.070 |
Why?
|
Biomarkers | 1 | 2010 | 554 | 0.070 |
Why?
|
Chicago | 1 | 2010 | 869 | 0.070 |
Why?
|
Risk Factors | 2 | 2010 | 2224 | 0.070 |
Why?
|
Endocarditis, Bacterial | 1 | 2006 | 10 | 0.060 |
Why?
|
Critical Care | 1 | 2008 | 180 | 0.060 |
Why?
|
Bone Diseases | 1 | 2005 | 20 | 0.060 |
Why?
|
Aged, 80 and over | 3 | 2010 | 4459 | 0.060 |
Why?
|
Bacteremia | 1 | 2006 | 94 | 0.060 |
Why?
|
Joint Diseases | 1 | 2005 | 101 | 0.060 |
Why?
|
Young Adult | 1 | 2010 | 1855 | 0.060 |
Why?
|
Drug Administration Schedule | 2 | 2013 | 152 | 0.050 |
Why?
|
Time Factors | 3 | 2010 | 1336 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2011 | 325 | 0.040 |
Why?
|
Blood | 1 | 2013 | 18 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2015 | 588 | 0.030 |
Why?
|
Creatine Kinase | 1 | 2013 | 21 | 0.030 |
Why?
|
Survival Analysis | 1 | 2013 | 246 | 0.030 |
Why?
|
Pseudomonas | 1 | 2011 | 1 | 0.020 |
Why?
|
Drug Interactions | 1 | 2011 | 36 | 0.020 |
Why?
|
Pseudomonas Infections | 1 | 2011 | 40 | 0.020 |
Why?
|
Pseudomonas aeruginosa | 1 | 2011 | 53 | 0.020 |
Why?
|
Bilirubin | 1 | 2011 | 11 | 0.020 |
Why?
|
Liposomes | 1 | 2011 | 13 | 0.020 |
Why?
|
Creatinine | 1 | 2011 | 47 | 0.020 |
Why?
|
Contrast Media | 1 | 2011 | 68 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2011 | 209 | 0.020 |
Why?
|
Health Services Research | 1 | 2010 | 38 | 0.020 |
Why?
|
Cohort Studies | 1 | 2015 | 1781 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2009 | 131 | 0.020 |
Why?
|
Survival Rate | 1 | 2009 | 308 | 0.020 |
Why?
|
Age Factors | 1 | 2011 | 716 | 0.020 |
Why?
|
Incidence | 1 | 2011 | 731 | 0.020 |
Why?
|
Knowledge | 1 | 2008 | 15 | 0.020 |
Why?
|
Inpatients | 1 | 2009 | 132 | 0.020 |
Why?
|
Problem Solving | 1 | 2008 | 47 | 0.020 |
Why?
|
Vancomycin | 1 | 2008 | 50 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2010 | 266 | 0.020 |
Why?
|
Cognition | 1 | 2015 | 1265 | 0.020 |
Why?
|
Hospitalization | 1 | 2010 | 292 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2011 | 913 | 0.020 |
Why?
|
beta-Lactamases | 1 | 2008 | 81 | 0.020 |
Why?
|
Communication | 1 | 2008 | 119 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2008 | 140 | 0.020 |
Why?
|
Decision Making | 1 | 2008 | 203 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2007 | 311 | 0.020 |
Why?
|
Vancomycin Resistance | 1 | 2006 | 26 | 0.020 |
Why?
|
United States | 1 | 2011 | 1943 | 0.020 |
Why?
|
Animals | 1 | 2007 | 3510 | 0.010 |
Why?
|